WALTHAM, Mass.--(BUSINESS WIRE)--N-of-One, Inc., a leading provider of molecular interpretation and therapeutic strategies for personalized cancer care, today announced a partnership with Fox Chase Cancer Center in Philadelphia, to provide molecular interpretation and treatment strategy analysis for genome sequencing and testing provided to advanced stage cancer patients through the Cancer Genome Institute at Fox Chase. Financial terms of the agreement are not disclosed. Under the terms of the agreement, N-of-One will analyze the molecular profile and mutations identified through genome sequencing of each patient’s cancer and deliver comprehensive treatment strategy profiles, including data on approved and investigational therapies to Fox Chase physicians who have ordered the CancerCode-45 sequencing for a patient. The treatment strategy profile interprets and informs the findings from the test.
